Glucose lowering by continuous tube feeding and Vildagliptin in addition to insulin in hyperglycemic acute stroke patients. - GLUCOVAS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-007020-25-NL

Enrollment

Registered

2008-12-29

Start date

2009-04-03

Completion date

Unknown

Last updated

2013-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperglycemia in acute ischemic stroke patients MedDRA version: 9.1 Level: LLT Classification code 10020635 Term: Hyperglycaemia MedDRA version: 9.1 Level: LLT Classification code 10023027 Term: Ischaemic stroke NOS

Interventions

Trade Name: Vildagliptin Product Name: Gavlus Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: Vildagliptine CAS Number: DPP-4 Other descriptive name: Dipeptidyl peptidase 4 (DPP-4) inh

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Acute ischemic supratentorial stroke hyperglycemia on admission (i.e. blood glucose > 7.0 mmol/) informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: younger than 18 years history of insulin use renal deficiency

Design outcomes

Primary

Measure	Time frame
Main Objective: To control hyperglycemia for five consecutive days in acute ischemic stroke patients;Secondary Objective: To investigate if tight glycemic control in improves outcome in patients with ischemic stroke.;Primary end point(s): mean glucose number of hypoglycemic episodes	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026